Clinical trials: Antitumor Drug
Endometrial Neoplasms, Ovarian Neoplasms
A Study of Catequentinib Hydrochloride (AL3818) in Endometrial, LGSOC, STS or GBM Cancers
This phase 1b/2a study evaluates the investigational oral drug catequentinib hydrochloride (AL3818), given alone or with AL58805, temozolomide, or lomustine (CCNU), in adults with advanced or metastatic solid tumors.
- Conditions
- Endometrial Neoplasms, Ovarian Neoplasms, Soft Tissue Sarcoma (STS), Glioblastoma
- Trial name
- NCT07811297
- Testing
- AL58805, AL3818, Temozolomide (TMZ)
- Where
- United States
- Volunteers
- 138 people
- Sponsor
- Advenchen Pharmaceuticals, LLC.
Ewing Sarcoma, Ewing Family of Tumors
A Trial For Participants With Ewing's Sarcoma Treated With Vigil in Combination With Irinotecan and Temozolomide
The goal of this clinical trial was to compare participants with first relapse or refractory Ewing's sarcoma when treated with investigational product (Vigil) in addition to the standard treatment of irinotecan and temozolomide…
- Conditions
- Ewing Sarcoma, Ewing Family of Tumors, Ewing's Tumor Metastatic, Ewing's Sarcoma Metastatic
- Trial name
- VITA (NCT03495921)
- Testing
- Vigil, Irinotecan, Temozolomide
- Where
- 15 sites in United States
- Volunteers
- 32 people
- Sponsor
- Gradalis, Inc.
Non-small Cell Lung Cancer
BPI-7711 Capsule in Patients With EGFR Mutation T790M Positive Non-small Cell Lung Cancer
Lung cancer has the highest incidence rate in China and is also a very common cancer in the world. BPI-7711 is a new drug developed for patients with non-small cell lung cancer.
- Trial name
- NCT03386955
- Testing
- BPI-7711 Capsule
- Where
- 4 sites in China
- Volunteers
- 215 people
- Sponsor
- Beta Pharma Shanghai
Advanced Breast Cancer
Study of Efficacy and Safety of LEE011 in Men and Postmenopausal Women With Advanced Breast Cancer.
The main aim of this study was to evaluate the efficacy and safety of adding ribociclib to fulvestrant in men and postmenopausal women with hormone receptor positive (HR+), HER2-negative advanced breast cancer.
- Trial name
- MONALEESA-3 (NCT02422615)
- Testing
- Ribociclib, Fulvestrant
- Where
- 174 sites in United States, Australia and 28 more
- Volunteers
- 726 people
- Sponsor
- Novartis Pharmaceuticals
Solid Tumours
A Phase 1/2a Study of LON002 in Subjects With Advanced Solid Tumours
This clinical trial will assess whether a medicine called artemether, currently used at a lower dose to treat malaria, could also be useful in treating cancer.
- Trial name
- LON002-002 (NCT02263950)
- Testing
- Artemether
- Where
- 2 sites in United Kingdom
- Volunteers
- 87 people
- Sponsor
- LondonPharma Ltd.
EGFR, Non-Small Cell Lung Cancer
Neoadjuvant Befotertinib Combined Bevacizumab or Platinum-based Double Chemotherapy for Resectable Locally-advanced EGFR Mutation-positive Non-Small Cell Lung Cancer
This study targeted patients with resectable stage II-IIIA non-small cell lung cancer with EGFR mutation
- Conditions
- EGFR, Non-Small Cell Lung Cancer, Locally Advanced Non-Small Cell Lung Cancer, Pemetrexed
- Trial name
- NCT06755684
- Testing
- Befotertinib combined Bevacizumab, Befotertinib combined platinum-based double chemotherapy
- Where
- China
- Volunteers
- 60 people
- Sponsor
- Peng Zhang
Platinum-resistant Ovarian Cancer, Platinum-refractory Ovarian Carcinoma
Chk2 Inhibitor for Recurrent EpitheliAl periToneal, fallopIan or oVarian cancEr (CREATIVE Phase IA Trial)
This study aims to assess the safety and tolerability of PHI-101 in patients with platinum-resistance/refractory ovarian, fallopian tubal, and primary peritoneal cancer.
- Conditions
- Platinum-resistant Ovarian Cancer, Platinum-refractory Ovarian Carcinoma, Platinum-Resistant Fallopian Tube Carcinoma, Platinum-Resistant Primary Peritoneal Carcinoma
- Trial name
- CREATIVE (NCT04678102)
- Testing
- PHI-101 administration
- Where
- South Korea
- Volunteers
- 36 people
- Sponsor
- Seoul National University Hospital
Lung Neoplasm Malignant, Carcinoma, Non-Small-Cell Lung
(Concerto) Study of BLU-451 in Advanced Cancers With EGFR Exon 20 Insertion Mutations
This is a Phase 1/2, open-label first-in-human study of the safety, pharmacokinetics (PK), pharmacodynamics, and anti-tumor activity of BLU-451 monotherapy and BLU-451 in combination with platinum-based chemotherapy (carboplatin…
- Conditions
- Lung Neoplasm Malignant, Carcinoma, Non-Small-Cell Lung, Respiratory Tract Neoplasms, Neoplasms
- Trial name
- NCT05241873
- Testing
- BLU-451, Carboplatin, Pemetrexed
- Where
- 23 sites in United States, Canada and 3 more
- Volunteers
- 103 people
- Sponsor
- Blueprint Medicines Corporation
Advanced Malignant Solid Tumors
JSKN022 in Subjects With Advanced Malignant Solid Tumors
The goal of this clinical trial is to learn if drug JSKN022 is safe to treat patients with advanced malignant solid tumors. It will also learn about the pharmacokinetic/ pharmacodynamic profiles and preliminary antitumor activity…
- Trial name
- NCT07292402
- Testing
- JSKN022
- Where
- China
- Volunteers
- 225 people
- Sponsor
- Jiangsu Alphamab Biopharmaceuticals Co., Ltd
Advanced Solid Tumors
A Study to Evaluate the Safety, Tolerability of DN1508052-01 in Advanced Solid Tumors
This is a phase I, open-label, multicenter study in adult patients with advanced solid tumors that have progressed despite standard therapy or for which no standard therapy exists.
- Trial name
- NCT03934359
- Testing
- DN1508052-01
- Where
- 3 sites in United States
- Volunteers
- 19 people
- Sponsor
- Shanghai De Novo Pharmatech Co., Ltd.
Acute Leukemia of Ambiguous Lineage, B Acute Lymphoblastic Leukemia
Testing the Addition of the Anti-cancer Drug Venetoclax and/or the Anti-cancer Immunotherapy Blinatumomab to the Usual Chemotherapy Treatment for Infants With Newly Diagnosed KMT2A-rearranged or KMT2A-non-rearranged Leukemia
This phase II trial tests the addition of venetoclax and/or blinatumomab to usual chemotherapy for treating infants with newly diagnosed acute lymphoblastic leukemia (ALL) with a KMT2A gene rearrangement (KMT2A-rearranged [R]) or…
- Trial name
- NCT06317662
- Testing
- Asparaginase Erwinia chrysanthemi, Biospecimen Collection, Blinatumomab
- Where
- 117 sites in United States, Puerto Rico
- Volunteers
- 153 people
- Sponsor
- National Cancer Institute (NCI)
Solid Cancer
A Study to Evaluate the Effects of Combining Cabazitaxel With Cisplatin Given Every 3 Weeks in Patients With Advanced Solid Cancer
This study is designed as a phase 1, multicenter, open-label, single arm, dose-escalation, study of Cabazitaxel in combination with cisplatin, to determine safety, pharmacokinetics (PK), and efficacy in solid tumors (parts 1 and…
- Trial name
- NCT00925743
- Testing
- cabazitaxel (XRP6258)
- Where
- 7 sites in United States
- Volunteers
- 76 people
- Sponsor
- Sanofi
Triple-Negative Breast Cancer
A Study of Ipatasertib in Combination With Atezolizumab and Paclitaxel as a Treatment for Participants With Locally Advanced or Metastatic Triple-Negative Breast Cancer
This study evaluated the efficacy and safety of ipatasertib in combination with atezolizumab and paclitaxel in locally advanced or metastatic Triple-Negative Breast Cancer (TNBC) previously untreated in this setting.
- Trial name
- NCT04177108
- Testing
- Atezolizumab, Ipatasertib, Paclitaxel
- Where
- 182 sites in United States, Argentina and 35 more
- Volunteers
- 242 people
- Sponsor
- Hoffmann-La Roche
Cancer, Atrial Fibrillation
Management of Atrial Fibrillation in Patients With Cancer (MAFIC Study)
The primary objective is to assess the safety and efficacy of switching from direct oral anticoagulants to low molecular weight heparin in cancer patients during antineoplastic therapy
- Trial name
- MAFIC (NCT04508855)
- Testing
- Low molecular weight heparin
- Where
- 2 sites in Greece
- Sponsor
- AHEPA University Hospital
Advanced Cancer, Metastatic Cancer
A Study of Merestinib (LY2801653) in Japanese Participants With Advanced or Metastatic Cancer
The main purpose of this study is to evaluate tolerability of merestinib monotherapy or in combination with other anti-cancer agents in Japanese participants with advanced and/or metastatic cancer.
- Conditions
- Advanced Cancer, Metastatic Cancer, Biliary Tract Carcinoma, Cholangiocarcinoma
- Trial name
- NCT03027284
- Testing
- Merestinib, Cisplatin, Gemcitabine
- Where
- 2 sites in Japan
- Volunteers
- 19 people
- Sponsor
- Eli Lilly and Company
Non-Small Cell Lung Cancer
Study of Alimta® (Pemetrexed) Plus VELCADE® (Bortezomib) or Alimta Alone or VELCADE Alone in Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer Who Have Failed Prior Therapy
The purpose of this study is to establish the objective response rate (complete response + partial response), following treatment with Alimta plus VELCADE, Alimta alone, or VELCADE alone in patients with locally advanced or…
- Trial name
- NCT00343720
- Testing
- VELCADE, Alimta
- Where
- Belgium
- Sponsor
- Millennium Pharmaceuticals, Inc.
Colorectal Neoplasms, Trifluridine and Tipiracil
Initial Attack on Latent Metastasis Using TAS-102 for ct DNA Identified Colorectal Cancer Patients After Curative Resection
This trial is a randomized, double-blind, multinational Phase III study to evaluate the efficacy and safety of preemptive treatment with FTD/TPI compared with administration of placebo as follow-up, which is the standard of care…
- Conditions
- Colorectal Neoplasms, Trifluridine and Tipiracil, Circulating Tumor DNA
- Trial name
- ALTAIR (NCT04457297)
- Testing
- trifluridine and tipiracil
- Where
- 39 sites in Japan, Taiwan
- Volunteers
- 243 people
- Sponsor
- National Cancer Center Hospital East
Breast Cancer, Breast Cancer Stage IV
A Study of Mirdametinib on Its Own or in Combination With Fulvestrant in People With Solid Tumor Cancer
The purpose of this study to find out whether mirdametinib is a safe treatment for people with advanced solid tumor cancer that has certain mutations.
- Conditions
- Breast Cancer, Breast Cancer Stage IV, HER2-negative Breast Cancer, Solid Carcinoma
- Trial name
- NCT05054374
- Testing
- Mirdametinib, Fulvestrant
- Where
- 4 sites in United States
- Volunteers
- 6 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Solid Tumors (Phase 1)
First-in-Human Study of ADCE-B05 in Patients With Advanced Solid Tumors
The main purpose of the study is to determine the Maximum Tolerated Dose (MTD), the Recommended Expansion Dose and the safety and tolerability of ADCE-B05 when given as a single therapy over a range of different dose levels.
- Trial name
- NCT07362888
- Testing
- ADCE-B05
- Where
- 7 sites in United States, Australia
- Volunteers
- 180 people
- Sponsor
- Adcendo ApS
Haematological Malignancy, Malignant Neoplasm
DETERMINE Trial Treatment Arm 07: Dabrafenib in Combination With Trametinib in Adult, Paediatric and Teenage/Young Adult Patients With BRAF V600 Mutation-Positive Cancers.
This clinical trial is looking at two drugs called dabrafenib and trametinib. Dabrafenib and trametinib are approved as standard of care treatment for adult patients with melanoma (a type of skin cancer) or lung cancer and in…
- Conditions
- Haematological Malignancy, Malignant Neoplasm, Lymphoproliferative Disorders, Neoplasms by Histologic Type
- Trial name
- DETERMINE (NCT07440290)
- Testing
- Dabrafenib, Trametinib
- Where
- 27 sites in United Kingdom
- Volunteers
- 30 people
- Sponsor
- Cancer Research UK